The Patent Finder

Terms ending in 2044

Genentech, Inc.

Every in-force patent on Genentech, Inc.'s record whose computed term ends in 2044, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,770,713Generative Protein Design with Composable Energy-Based Models
In force
 · Medium confidence
Genentech, Inc.In forceMedium confidence
US 12,338,460Method for Generating T Cell Lineage Populations from Stem/Progenitor Cells
In force
 · High confidence
Genentech, Inc.In forceHigh confidence
US 12,749,555Multipole Moment Based Coarse Grained Representation of Antibody Electrostatics
In force
 · Medium confidence
Genentech, Inc.In forceMedium confidence
US 12,398,953Rapid Depressurization Controlled Ice Nucleation in Pharmaceutical Freeze-Drying
In force
 · High confidence
Purdue Research FoundationIn forceHigh confidence
US 12,516,118Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibodies and ANTI-CD79B Antibody Drug Conjugates
In force
 · High confidence
Genentech, Inc.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Genentech, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited